Oktem, Elif KubatAydin, BusraYazar, MetinArga, Kazim YalcinGenetik ve Biyomühendislik / Genetic and Bio-Engineering2024-05-252024-05-25202250895-86961559-116610.1007/s12031-022-02071-12-s2.0-85139227814https://doi.org/10.1007/s12031-022-02071-1https://hdl.handle.net/20.500.14517/979Amyotrophic lateral sclerosis (ALS) is a fatal disease of motor neurons that mainly affects the motor cortex, brainstem, and spinal cord. Under disease conditions, microglia could possess two distinct profiles, M1 (toxic) and M2 (protective), with the M2 profile observed at disease onset. SOD1 (superoxide dismutase 1) gene mutations account for up to 20% of familial ALS cases. Comparative gene expression differences in M2-protective (early) stage SOD1(G93A) microglia and age-matched SOD1(G93A) motor neurons are poorly understood. We evaluated the differential gene expression profiles in SOD1(G93A) microglia and SOD1(G93A) motor neurons utilizing publicly available transcriptomics data and bioinformatics analyses, constructed biomolecular networks around them, and identified gene clusters as potential drug targets. Following a drug repositioning strategy, 5 small compounds (belinostat, auranofin, BRD-K78930611, AZD-8055, and COT-10b) were repositioned as potential ALS therapeutic candidates that mimic the protective state of microglia and reverse the toxic state of motor neurons. We anticipate that this study will provide new insights into the ALS pathophysiology linking the M2 state of microglia and drug repositioning.eninfo:eu-repo/semantics/openAccessSOD1 mutationAmyotrophic lateral sclerosisTranscriptomicDrug repositioningRepositioned therapeuticsArticleQ3Q2721123602376WOS:00086221810000136178612